As the top cancer researchers gather in Chicago, the world's largest CRO is weighing in on how best to steer the future of oncology drug development, arguing that picking the right patients and biomarkers in early stages can mean the difference between a blockbuster and a late-phase failure.
Between billion-dollar IPOs and big-name exclusive partnerships, it's a good time to be a giant in the CRO world. However, all the recent consolidation has made it harder for mid-size outfits to compete, as medium-capped players lack the capacity to challenge heavyweights and don't offer the kind of niche services that keep small CROs afloat.
DKSH, the Asia-focused drug marketer, has expanded its heft in South Korea, opening a new distribution in Seoul aimed to help its medical device clients place products around the country.
QPS is reaching out to Hepregen to boost its early stage development offerings, licensing the company's "liver-in-a-dish" technology for drug metabolism and pharmacokinetic testing.
CMO UPM Pharmaceuticals is buying a 500,000-square-foot plant from Pfizer for an undisclosed sum, a huge boost to its capacity that comes paired with a big-name new client.
India is on its way to requiring clinical trial participants to state their consent to a video camera before undergoing treatment, a move aimed to reduce the number of patients deluded into studies with false information.
Parexel International has cut the ribbon on a facility in Shenyang, China, adding to the CRO's heft in the country and giving it a platform to expand the adoption of its eClinical offerings.
German CRO Cenix BioScience has agreed to handle preclinical work for Debiopharm's oncology pipeline, using its high-content assays to identify biomarkers.
U.K. CRO ClinTec International has its sites set on Turkey, planning to open an office in Istanbul to tap the growing demand for clinical research in the Middle East.
Diagnostics outfit Corgenix has paired up with Eli Lilly to develop tests for the drugmaker's oncology pipeline, a step forward in the company's efforts to expand its contract services business.
Nordion's constantly evolving business will soon be without proprietary pharma, as the company has agreed to ship out its targeted therapies business for $200 million.
Global CRO Quintiles is planning to slash 400 jobs this year, the company disclosed in a regulatory filing, primarily from its product development and healthcare services departments.
Navidea Biopharmaceuticals has seen its fair share of CMO troubles, as problems with its last contract manufacturer delayed a much-anticipated FDA approval. Now, the diagnostics developer is hitching up with Nordion to manufacture an in-development imaging agent, hoping to avoid more production setbacks.
Perhaps encouraged by the success of its North Carolina neighbor Quintiles, PRA is making moves toward an IPO of its own, filing a confidential draft registration form with the SEC.
BioDuro, PPD's China-based drug discovery business, has opened a state-of-the-art facility in Shanghai, a lab the company says will help it cozy up to clients in the growing Asian biopharmaceutical world.
Amid repeated pipeline struggles and an R&D re-think, Merck KGaA has signed an exclusive deal with the newly public Quintiles, launching a novel collaboration that will give the CRO a seat at the decisionmaking table.
WuXi PharmaTech, China's largest CRO, has big expectations for 2013, and the company is well on its way to following through, posting an 11.7% revenue jump in the first quarter.
Stat Research, a Buenos Aires-based CRO, has reached out to eClinical provider Datatrak in an effort to reduce clinical trial costs and accelerate drug development timelines.
GlaxoSmithKline is turning to market-expansion contractors DKSH to push its antibiotic products in Hong Kong, part of the drugmaker's efforts to cash in on booming Asian demand.
PRA has cut the ribbon on a new facility in Wales, planning to add about 100 new jobs in its informatics unit with help from the local government.